Biotech RadarJobs updated

COMPANY

Biomea Fusion

HQ: San Carlos, CA source · biomeafusion.com ↗ · West Coast

Clinical Phase 2

Keywords: small molecule metabolic disease of metabolism diabetes mellitus Acute Myeloid Leukemia Type 2 Diabetes Plasma-Cell Myeloma Type 1 Diabetes Mellitus Obesity Type 2 Diabetes Mellitus Acute Lymphoblastic Leukemia Acute Mixed-Phenotype Leukemia Refractory Progression Diffuse Large B Cell Lymphoma Multiple Myeloma Lymphoma Non-Hodgkin Lymphoma Myelomatosis Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Non Small Cell Lung Cancer Pancreatic Cancer Colorectal Cancer NSCLC CRC Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Stage III Colorectal Cancer Stage IV Colorectal Cancer Stage III NSCLC Stage IV NSCLC KRAS Mutation-Related Tumors BMF-219 BMF-500 icovamenib BMF-650

Location: San Carlos, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$65.0MRaised (2 yrs)9Trials (company is sponsor)

Timeline

  1. Trial start 2: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy source ↗
  2. Trial start 2: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets source ↗
  3. Trial start Phase 1: Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants source ↗
  4. Raise Follow-on offering: $25M (total, as published), announced Oct 7, 2025. Source: SEC filing. source ↗
  5. Trial start Phase 1: Food Effect Study in Healthy Volunteers source ↗
  6. Raise Follow-on offering: $40M (total, as published), announced Jun 17, 2025. Source: SEC filing. source ↗
  7. Trial start 2: Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus source ↗
  8. Trial start 1: A Phase 1 Study of BMF-500 in Adults With Acute Leukemia source ↗
  9. Trial start Phase 1: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer source ↗
  10. Trial start Phase 1/Phase 2: Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) source ↗
  11. Trial start Phase 1: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $65.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT05918692A Phase 1 Study of BMF-500 in Adults With Acute Leukemia1CompletedJul 26, 2023Jan 1, 2026 (actual)
NCT06152042Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus2CompletedDec 28, 2023May 20, 2025 (actual)
NCT07502495Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets2Active, not recruitingMar 27, 20262027-03 (estimated)
NCT07502508Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy2RecruitingApr 30, 20262027-06 (estimated)
NCT07223216Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult ParticipantsPhase 1Active, not recruitingOct 23, 20252026-05 (estimated)
NCT07254286Food Effect Study in Healthy VolunteersPhase 1CompletedSep 11, 2025Jan 14, 2026 (actual)
NCT05731544Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)Phase 1/Phase 2CompletedAug 17, 2022Nov 18, 2024 (actual)
NCT05153330Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLPhase 1TerminatedJan 24, 2022Feb 13, 2025 (actual)
NCT05631574Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal CancerPhase 1TerminatedJan 12, 2023Jan 15, 2025 (actual)
Feedback